List of Excipients in Branded Drug MAVENCLAD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
EMD Serono Inc	MAVENCLAD	cladribine	44087-4000	HYDROXYPROPYL BETADEX
EMD Serono Inc	MAVENCLAD	cladribine	44087-4000	MAGNESIUM STEARATE
EMD Serono Inc	MAVENCLAD	cladribine	44087-4000	SORBITOL

MAVENCLAD Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: September 24, 2026

MAVENCLAD is an oral cladribine product whose commercial value depends on a compact tablet, controlled excipient profile, reliable dose delivery, and a dosing schedule that limits annual treatment exposure. The U.S. product is a 10 mg tablet supplied by EMD Serono, a business of Merck KGaA, for adults with relapsing forms of multiple sclerosis and active secondary progressive multiple sclerosis.[1]

The most practical commercial opportunities are in generic or authorized-generic development, excipient substitution, taste and swallowability improvements, supply-chain redundancy, and manufacturing services. Because cladribine is a small molecule, biosimilar pathways are irrelevant. Regulatory and patent risk is concentrated in abbreviated new drug application strategy, formulation equivalence, method-of-use claims, and any remaining listed patents rather than biologic comparability.

What excipients are used in MAVENCLAD tablets?

MAVENCLAD tablets use a relatively simple excipient system. The product contains cladribine as the active ingredient and uses hydroxypropyl betadex, sorbitol, and magnesium stearate in the tablet core. The film coating contains hypromellose, titanium dioxide, and talc, according to product information for the marketed tablet.[1,2]

Formulation element	Publicly identified material	Primary function
Active ingredient	Cladribine, 10 mg per tablet	Purine nucleoside analog
Solubilizing or complexing excipient	Hydroxypropyl betadex	Improves drug handling, wetting, and apparent solubility
Bulking agent	Sorbitol	Tablet mass and mouthfeel
Lubricant	Magnesium stearate	Ejection and manufacturing control
Film former	Hypromellose	Tablet coating and protection
Opacifier or pigment	Titanium dioxide	Appearance and light protection
Anti-tacking or coating aid	Talc	Coating process performance

The absence of a complex multiparticulate or modified-release system reduces manufacturing burden. It also narrows the main formulation-development questions to dissolution, content uniformity, solid-state behavior, impurity control, coating performance, and excipient compatibility.

How does the MAVENCLAD excipient system affect commercial development?

The excipient strategy is commercially attractive because it uses established pharmaceutical materials with broad supplier availability. Hydroxypropyl betadex is the most technically distinctive component. Its use may create a development advantage by improving cladribine dispersion or dissolution, but it also creates the largest opportunity for non-infringing reformulation.

A generic developer would normally evaluate three formulation routes:

1. Direct replication. Use the same excipient classes and closely match the reference product's dissolution and stability profile.
2. Excipient substitution. Replace hydroxypropyl betadex, sorbitol, or the coating system with functionally equivalent materials.
3. Performance redesign. Use a different solubilization or granulation platform while demonstrating pharmaceutical equivalence and bioequivalence.

Direct replication is usually the lowest technical-risk option. Substitution can reduce cost or supply risk but may increase comparative dissolution, stability, and bioequivalence work. A redesign may create stronger product differentiation but is less suitable for a conventional ANDA unless the resulting product remains pharmaceutically equivalent and bioequivalent.

What formulation characteristics matter most for cladribine tablets?

Dissolution and wetting

Cladribine is administered at a low tablet strength, but the active ingredient has a narrow commercial presentation. The formulation must achieve consistent dissolution across the product's shelf life and manufacturing scale. Hydroxypropyl betadex may support wetting and solubilization, making it an important variable in comparative formulation work.

The critical development tests are likely to include:

• Comparative dissolution across multiple pH conditions
• Tablet disintegration
• Assay and content uniformity
• Related substances and degradation products
• Moisture uptake
• Stability under long-term and accelerated conditions
• Compatibility between cladribine and the excipient system

Dose flexibility

MAVENCLAD treatment is weight-based and uses tablets over short treatment periods. The label describes two annual treatment courses, with each course consisting of two treatment cycles separated by approximately one month. Each cycle generally lasts four or five days, depending on body weight.[1]

Because the product is distributed through a structured dosing schedule, commercial value depends on accurate tablet counting and packaging. A generic developer may gain operational value through clearer packaging, calendarized blister packs, or dispensing controls, provided the presentation does not create regulatory or prescriber confusion.

Stability and packaging

Cladribine products require protection from environmental exposure and must maintain assay and impurity specifications through the labeled shelf life. A commercial formulation program should evaluate:

• High-barrier blister materials
• Bottle systems with desiccants
• Light protection
• Moisture transmission
• Tablet friability after coating
• Compatibility between the coating and packaging system

Packaging improvements may be commercially valuable even when the tablet composition remains close to the reference product. They can reduce waste, improve adherence to the two-course regimen, and support specialty-pharmacy distribution.

What patent protection covers MAVENCLAD?

MAVENCLAD contains cladribine, an established small-molecule active ingredient. Core composition-of-matter protection for cladribine is not the principal barrier to generic entry. The relevant protection is more likely to involve later-filed claims covering pharmaceutical compositions, tablet formulations, dosing regimens, treatment of multiple sclerosis, or manufacturing processes.

A complete freedom-to-operate review should separate four categories:

Protection category	Commercial relevance
Cladribine composition patents	Likely limited because the active ingredient is old
Tablet or formulation patents	Could affect excipient selection, solubilization, coating, or stability
Method-of-use patents	Could target treatment regimens, patient populations, or disease activity
Process and manufacturing patents	Could affect granulation, crystallization, impurity control, or scale-up

Public product labeling identifies the formulation components but does not establish that each excipient or excipient combination is separately patented. Excipients are generally available from multiple suppliers, and the key legal question is whether a specific combination or manufacturing process falls within an enforceable claim.

What is the Orange Book status of MAVENCLAD?

MAVENCLAD is approved in the United States under NDA 022561. The FDA Orange Book is the controlling source for current listed patents, exclusivity codes, and any paragraph IV certification activity associated with the NDA.[3]

MAVENCLAD is a small-molecule tablet, so an ANDA is the expected generic pathway. A prospective applicant would review:

• Patent listings associated with NDA 022561
• Patent-use codes covering multiple sclerosis treatment
• Any listed expiration dates and pediatric extensions
• Whether a proposed label requires a section viii carve-out
• Any first-filer or 180-day exclusivity position
• FDA suitability of the proposed formulation and packaging

Patent expiry should not be inferred from the active ingredient's age. Later formulation or method patents can delay a fully labeled generic launch even when cladribine itself is no longer protected.

When does MAVENCLAD lose exclusivity?

Regulatory exclusivity and patent exclusivity are separate. The timing of generic entry depends on the later of applicable regulatory barriers, enforceable patent claims, and the ability of an ANDA applicant to obtain approval.

MAVENCLAD's commercial protection should be assessed through four dates:

Timing issue	Relevance
NDA approval date	Determines the starting point for certain regulatory exclusivity periods
Listed patent expiration	Can block approval or launch depending on the patent and certification
Paragraph IV litigation date	May trigger a 30-month stay under applicable circumstances
Pediatric exclusivity	Can add six months to certain listed protections

The product's U.S. approval occurred in 2019.[1] Any original new-drug exclusivity is therefore a historical issue rather than the principal current barrier. The live commercial question is the status of listed formulation and method-of-use patents and whether an applicant can launch with a carved-out label.

Are there Paragraph IV challenges to MAVENCLAD?

A Paragraph IV challenge is the principal legal route for a generic applicant that believes a listed patent is invalid, unenforceable, or not infringed. Publicly available FDA and court records should be reviewed together because Orange Book listings show the regulatory position, while district-court dockets show litigation and settlement activity.[3,4]

The main challenge scenarios are:

• No listed patent barrier: ANDA approval can proceed after applicable exclusivity ends.
• Method-of-use patent only: A section viii carve-out may permit approval for non-protected uses if the label can be lawfully limited.
• Formulation patent: The applicant may need a Paragraph IV certification or a different formulation.
• Litigation settlement: Entry may occur on an agreed date, subject to the settlement's terms and competition-law constraints.

No biosimilar challenge applies because MAVENCLAD is not a biologic. The relevant competitors are generic cladribine tablets and potentially authorized-generic versions.

What formulation patents could affect generic MAVENCLAD?

Formulation patents could target the use of hydroxypropyl betadex, a particular cladribine-to-excipient ratio, a dissolution profile, a manufacturing sequence, or a stability result. A generic developer should not assume that replacing one excipient automatically avoids infringement. Patent claims can cover functional combinations, process steps, or broad composition ranges.

The highest-risk technical areas are:

Hydroxypropyl betadex substitution

Replacing hydroxypropyl betadex with another cyclodextrin, polymer, surfactant, or wetting agent may reduce formulation-patent exposure. It may also change dissolution, impurity formation, tablet hardness, and bioavailability.

Sorbitol substitution

Sorbitol contributes bulk and may affect hygroscopicity, tablet compression, and mouthfeel. Mannitol, lactose, microcrystalline cellulose, or another polyol could provide alternative development routes, but each creates a new compatibility and dissolution profile.

Coating redesign

A different film-coating system can reduce dependence on the reference coating composition. It may also affect moisture protection, appearance, mechanical strength, and packaging stability.

Process redesign

Wet granulation, dry granulation, direct compression, or roller compaction could create different manufacturing and IP positions. Process changes must be assessed against impurity control and scale-up reproducibility.

What commercial opportunities exist in MAVENCLAD excipients?

Generic and authorized-generic supply

The largest opportunity is supplying excipients to generic manufacturers preparing an ANDA. Hydroxypropyl betadex is the most differentiated material in the disclosed formulation. Suppliers that can offer pharmaceutical-grade material with dependable batch consistency, regulatory documentation, and global supply are positioned better than commodity suppliers competing only on price.

Excipient substitution programs

A developer may pursue a lower-cost or more resilient formulation that removes dependence on a single specialized excipient. The value proposition is strongest where the substitute:

• Maintains comparable dissolution
• Reduces raw-material cost
• Improves moisture stability
• Has multiple qualified suppliers
• Simplifies regulatory documentation
• Avoids a relevant formulation patent

Specialty packaging

MAVENCLAD's intermittent, weight-based schedule creates demand for packaging that reduces dosing errors. Calendarized blister packs, cycle-specific packaging, and specialty-pharmacy fulfillment can support adherence and reduce dispensing complexity.

Contract development and manufacturing

CDMOs can offer value through:

• Cladribine tablet process development
• High-potency or containment manufacturing
• Comparative dissolution programs
• Stability and packaging qualification
• Commercial-scale coating
• Regulatory CMC support

The active ingredient is potent relative to the low tablet dose, so containment, cleaning validation, cross-contamination control, and analytical sensitivity are relevant manufacturing barriers.

Regional licensing

MAVENCLAD is marketed in multiple jurisdictions, but approval, reimbursement, packaging, and patent status differ by country. Regional opportunities may exist for local partners that can manage national variations, specialty distribution, and regulatory submissions. Licensing value is greater where multiple sclerosis treatment access is expanding and oral disease-modifying therapies are reimbursed.

How does MAVENCLAD compare with competing multiple sclerosis products?

MAVENCLAD differs from continuous oral therapies such as dimethyl fumarate and teriflunomide because it uses short, intermittent treatment courses rather than daily administration. It also competes with high-efficacy monoclonal antibodies and other disease-modifying therapies.

Product type	Administration pattern	Generic or biosimilar pathway	Excipient opportunity
MAVENCLAD	Short annual oral treatment courses	ANDA	Tablet composition, packaging, excipient substitution
Dimethyl fumarate	Daily oral dosing	ANDA	Enteric protection, gastrointestinal tolerability, polymorph control
Teriflunomide	Daily oral dosing	ANDA	Immediate-release tablet optimization
Monoclonal antibodies	Parenteral administration	Biosimilar or interchangeable biologic pathway	Protein stabilization, device, cold chain
S1P modulators	Daily oral dosing	ANDA	Solid-state control, dose flexibility, capsule or tablet design

MAVENCLAD's main formulation advantage is simplicity. Its main commercial disadvantage is the smaller addressable volume compared with daily oral multiple sclerosis products and the need for specialized prescribing and distribution.

What manufacturing and IP barriers exist for MAVENCLAD?

The main barriers are technical rather than raw-material scarcity:

1. Low-dose uniformity. The tablet must deliver consistent cladribine content at a 10 mg strength.
2. Containment. Manufacturing requires controls appropriate for a potent pharmacologically active compound.
3. Dissolution matching. Excipient substitution must preserve release behavior.
4. Impurity control. Process conditions, moisture, and excipient interactions can affect degradation.
5. Packaging qualification. The final pack must maintain stability and support a complex dosing schedule.
6. Patent clearance. Formulation, method-of-use, and process claims require separate review.
7. Clinical positioning. Generic uptake depends on payer substitution and continued specialist use.

What is the revenue exposure for MAVENCLAD?

MAVENCLAD revenue is exposed to four factors:

• The number of eligible patients with active disease
• Reimbursement for high-efficacy disease-modifying therapy
• Physician preference for intermittent oral dosing
• Timing of generic or authorized-generic entry

A generic entrant could compete on price, but the product's intermittent regimen limits annual tablet volume per patient. Commercial success would therefore depend on market access, distribution coverage, and substitution rules rather than high unit volume alone.

For excipient suppliers, the addressable opportunity is smaller than for high-volume chronic tablets but may carry higher technical value because of the specialized cyclodextrin component, potency controls, and regulatory documentation. For CDMOs, the opportunity is stronger in development, scale-up, and specialty packaging than in commodity tablet production.

What licensing deals affect MAVENCLAD?

MAVENCLAD is commercialized by Merck KGaA through its healthcare operations, including EMD Serono in the United States.[1] Public commercial information is concentrated on product commercialization and regional marketing rather than on an excipient-specific licensing transaction.

Potential licensing structures include:

• Regional rights to market cladribine tablets
• Authorized-generic supply arrangements
• Formulation technology licenses
• Excipient supply agreements
• CDMO development and manufacturing contracts
• Specialty-pharmacy or distribution partnerships

An excipient supplier is more likely to participate through a quality agreement, preferred-supplier arrangement, or technology-transfer project than through a high-value product license.

Key Takeaways

• MAVENCLAD is a 10 mg cladribine tablet with a relatively simple disclosed excipient system.
• Hydroxypropyl betadex is the most technically differentiated excipient and the leading target for substitution or supply-chain strategy.
• Sorbitol, magnesium stearate, hypromellose, titanium dioxide, and talc are established pharmaceutical materials with broad sourcing options.
• Generic competition would proceed through the ANDA pathway, not a biosimilar pathway.
• Formulation, method-of-use, and process patents matter more than old cladribine composition-of-matter protection.
• The strongest commercial opportunities are generic formulation development, excipient supply, specialty packaging, containment manufacturing, and regional licensing.
• Product simplicity lowers manufacturing complexity but does not eliminate dissolution, low-dose uniformity, stability, or IP risks.
• Commercial value depends on payer access and specialist adoption because the annual tablet volume per patient is limited.

FAQs

Can a generic MAVENCLAD use different excipients?

Yes. A generic may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling. The developer must also assess formulation-patent risk.

Is hydroxypropyl betadex essential to cladribine tablet performance?

It is part of the marketed formulation and may support wetting or solubilization, but its technical necessity must be established through comparative development. Alternative excipient systems may be possible.

Does MAVENCLAD require a biosimilar application?

No. MAVENCLAD is a small-molecule drug. A competing oral cladribine product would generally use the ANDA pathway if it meets the applicable requirements.

Could a different tablet coating create a commercial advantage?

Yes. A redesigned coating may improve moisture protection, appearance, mechanical durability, or manufacturing cost. It must preserve product quality and avoid relevant patent claims.

Why is packaging especially important for MAVENCLAD?

Treatment occurs in short, weight-based cycles separated by treatment-free periods. Cycle-specific packaging can reduce dosing errors, support specialty-pharmacy dispensing, and improve adherence.

References

1. EMD Serono, Inc. (2024). MAVENCLAD (cladribine) tablets, prescribing information. U.S. Food and Drug Administration.
2. European Medicines Agency. (2024). Mavenclad: EPAR product information. European Medicines Agency.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Courts. (2025). Public access to court electronic records. PACER.